UK begins inquiry into AstraZeneca's $39B buyout of Alexion
The UK’s Competition and Markets Authority opened an inquiry on Tuesday into AstraZeneca’s proposed $39 billion acquisition of Alexion.
By July 21, the CMA says it will decide whether the deal will result in a substantial lessening of competition within any markets in the UK. Those looking to comment on the deal have until June 3.
But with the US Federal Trade Commission signing off on the acquisition in April, and nine other countries, including Brazil and Canada, following suit, all signs point to a positive result from the UK.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.